Equities Analysts Issue Forecasts for TransCode Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:RNAZ)

Posted by Irma Garcia on Aug 21st, 2024

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright dropped their Q3 2024 earnings estimates for TransCode Therapeutics in a report issued on Thursday, August 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.51) per share for the quarter, down from their prior estimate of ($0.35). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($2.05) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.25) EPS.

TransCode Therapeutics Stock Performance

NASDAQ:RNAZ opened at $0.28 on Monday. TransCode Therapeutics has a one year low of $0.22 and a one year high of $128.00. The business has a fifty day moving average price of $0.67 and a 200-day moving average price of $0.78.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC bought a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned 0.84% of TransCode Therapeutics at the end of the most recent quarter.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.